{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:43:15Z","timestamp":1787949795566,"version":"build-2784847793"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Comorbid mental health symptoms impact 30\u201340% of cancer patients, significantly compromising treatment adherence and increasing mortality rates. Among patients undergoing radiation therapy, which is delivered with palliative intent in nearly half of all cases and for those nearing end-of-life, these rates may be even higher. Emerging research underscores the promising potential of psychedelic-assisted therapy (PAT) in alleviating cancer-related psychological distress. However, the perspectives of cancer patients on the therapeutic utility of psychedelics remain unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and materials<\/jats:title>\n                    <jats:p>Adult patients with a cancer diagnosis were recruited in Radiation Oncology Clinic between May 2023 and August 2024. They included patients being evaluated before, during, or after radiation therapy. Data on demographics, medical history, prior psychedelic use, and measures of mental health burden and quality of life using validated questionnaires were collected to assess interest in PAT and factors associated with such interest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>100 patients enrolled in the study. 43% expressed interest in PAT, while 31% were opposed, and 26% were unsure. Prior diagnoses of mental health disorders like anxiety and depression, prior recreational psychedelic use, younger age, and male sex were positively associated with interest in PAT. Notably, patients with higher levels of depression, worse spiritual well-being, worse demoralization, worse quality of life, and more pain, symptoms that are targeted with PAT, were more likely to be receptive to it. Hesitancy was primarily attributed to a lack of information, cited by 43% of those not interested or unsure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Psychedelic-assisted therapy represents a promising avenue to address critical gaps in cancer-related mental health care, and this study suggests that a substantial portion of cancer patients are receptive to and curious about this approach. The primary barrier to acceptance is informational, emphasizing the need for further research and education to dispel misconceptions and increase awareness of the safety and efficacy of psychedelic therapies. Future work should explore provider perspectives, patient outcomes, and the integration of PAT into palliative care frameworks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-025-02686-9","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T13:53:29Z","timestamp":1753106009000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Radiation therapy patients\u2019 interest in psychedelic-assisted therapy: results of a survey"],"prefix":"10.1186","volume":"20","author":[{"given":"Jino","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rufus","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akul","family":"Munjal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Hanubal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Hoyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin H.","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy P.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"issue":"2","key":"2686_CR1","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S1470-2045(11)70002-X","volume":"12","author":"AJ Mitchell","year":"2011","unstructured":"Mitchell AJ, Chan M, Bhatti H, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12(2):160\u201374. https:\/\/doi.org\/10.1016\/S1470-2045(11)70002-X.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2686_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.6004\/jnccn.2020.7620","volume":"19","author":"JP Harris","year":"2021","unstructured":"Harris JP, Kashyap M, Humphreys JN, Chang DT, Pollom EL. Longitudinal analysis of mental disorder burden among elderly patients with gastrointestinal malignancies. J Natl Compr Canc Netw. 2021;19(2):163\u201371. https:\/\/doi.org\/10.6004\/jnccn.2020.7620.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"2686_CR3","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1245\/s10434-012-2793-5","volume":"20","author":"\u00d3 Arrieta","year":"2013","unstructured":"Arrieta \u00d3, Angulo LP, N\u00fa\u00f1ez-Valencia C, et al. Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. Ann Surg Oncol. 2013;20(6):1941\u20138. https:\/\/doi.org\/10.1245\/s10434-012-2793-5.","journal-title":"Ann Surg Oncol"},{"issue":"23","key":"2686_CR4","doi-asserted-by":"publisher","first-page":"8912","DOI":"10.1002\/cam4.3509","volume":"9","author":"JP Harris","year":"2020","unstructured":"Harris JP, Kashyap M, Humphreys JN, Pollom EL, Chang DT. The clinical and financial cost of mental disorders among elderly patients with gastrointestinal malignancies. Cancer Med. 2020;9(23):8912\u201322. https:\/\/doi.org\/10.1002\/cam4.3509.","journal-title":"Cancer Med"},{"issue":"8","key":"2686_CR5","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1038\/s41380-022-01661-0","volume":"28","author":"J Moncrieff","year":"2023","unstructured":"Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry. 2023;28(8):3243\u201356. https:\/\/doi.org\/10.1038\/s41380-022-01661-0.","journal-title":"Mol Psychiatry"},{"key":"2686_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011006.pub2","author":"G Ostuzzi","year":"2015","unstructured":"Ostuzzi G, Matcham F, Dauchy S, Barbui C, Hotopf M. Antidepressants for the treatment of depression in people with cancer. Cochrane Database of Syst Rev. 2015. https:\/\/doi.org\/10.1002\/14651858.CD011006.pub2.","journal-title":"Cochrane Database of Syst Rev."},{"issue":"1","key":"2686_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12904-021-00889-x","volume":"20","author":"H Niles","year":"2021","unstructured":"Niles H, Fogg C, Kelmendi B, Lazenby M. Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies. BMC Palliat Care. 2021;20(1):191. https:\/\/doi.org\/10.1186\/s12904-021-00889-x.","journal-title":"BMC Palliat Care"},{"issue":"2","key":"2686_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/0269881119897615","volume":"34","author":"GI Agin-Liebes","year":"2020","unstructured":"Agin-Liebes GI, Malone T, Yalch MM, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020;34(2):155\u201366. https:\/\/doi.org\/10.1177\/0269881119897615.","journal-title":"J Psychopharmacol"},{"key":"2686_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2019.109735","volume":"96","author":"A Bahji","year":"2020","unstructured":"Bahji A, Forsyth A, Groll D, Hawken ER. Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2020;96: 109735. https:\/\/doi.org\/10.1016\/j.pnpbp.2019.109735.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"12","key":"2686_CR10","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181\u201397. https:\/\/doi.org\/10.1177\/0269881116675513.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"2686_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","volume":"68","author":"CS Grob","year":"2011","unstructured":"Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68(1):71. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2010.116.","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"2686_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","volume":"202","author":"P Gasser","year":"2014","unstructured":"Gasser P, Holstein D, Michel Y, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202(7):513\u201320. https:\/\/doi.org\/10.1097\/NMD.0000000000000113.","journal-title":"J Nerv Ment Dis"},{"issue":"3","key":"2686_CR13","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3934\/publichealth.2023043","volume":"10","author":"A Oyetunji","year":"2023","unstructured":"Oyetunji A, Huelga C, Bunte K, Tao R, Bellman V. Use of ketamine for depression and suicidality in cancer and terminal patients: Review of current data. AIMSPH. 2023;10(3):610\u201326. https:\/\/doi.org\/10.3934\/publichealth.2023043.","journal-title":"AIMSPH"},{"key":"2686_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-067194","author":"M Abbar","year":"2022","unstructured":"Abbar M, Demattei C, El-Hage W, et al. Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial. BMJ. 2022. https:\/\/doi.org\/10.1136\/bmj-2021-067194.","journal-title":"BMJ"},{"issue":"2","key":"2686_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.semradonc.2023.01.001","volume":"33","author":"TA Balboni","year":"2023","unstructured":"Balboni TA, Rades D. Palliative radiation oncology: personalized approaches to radiotherapeutic technologies, quality of life, and end-of-life cancer care. Semin Radiat Oncol. 2023;33(2):91\u20132. https:\/\/doi.org\/10.1016\/j.semradonc.2023.01.001.","journal-title":"Semin Radiat Oncol"},{"key":"2686_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n972","author":"Y Wu","year":"2021","unstructured":"Wu Y, Levis B, Sun Y, et al. Accuracy of the hospital anxiety and depression scale depression subscale (HADS-D) to screen for major depression: systematic review and individual participant data meta-analysis. BMJ. 2021. https:\/\/doi.org\/10.1136\/bmj.n972.","journal-title":"BMJ"},{"issue":"11","key":"2686_CR17","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1002\/cncr.29286","volume":"121","author":"AR Munoz","year":"2015","unstructured":"Munoz AR, Salsman JM, Stein KD, Cella D. Reference values of the functional assessment of chronic illness therapy-spiritual well-being: a report from the american cancer society\u2019s studies of cancer survivors. Cancer. 2015;121(11):1838\u201344. https:\/\/doi.org\/10.1002\/cncr.29286.","journal-title":"Cancer"},{"issue":"14","key":"2686_CR18","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1002\/cncr.30015","volume":"122","author":"S Robinson","year":"2016","unstructured":"Robinson S, Kissane DW, Brooker J, et al. Refinement and revalidation of the demoralization scale: The DS-II\u2014internal validity. Cancer. 2016;122(14):2251\u20139. https:\/\/doi.org\/10.1002\/cncr.30015.","journal-title":"Cancer"},{"issue":"5","key":"2686_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, et al. The european organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. JNCI J Natl Cancer Inst. 1993;85(5):365\u201376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"2","key":"2686_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4103\/0973-1075.84531","volume":"17","author":"SP Kumar","year":"2011","unstructured":"Kumar SP. Utilization of brief pain inventory as an assessment tool for pain in patients with cancer: a focused review. Indian J Palliat Care. 2011;17(2):108\u201315. https:\/\/doi.org\/10.4103\/0973-1075.84531.","journal-title":"Indian J Palliat Care"},{"issue":"5","key":"2686_CR21","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S0010-440X(68)80080-X","volume":"9","author":"R Mechaneck","year":"1968","unstructured":"Mechaneck R, Feldstein S, Dahlberg CC, Jaffe J. Experimental investigation of LSD as a psychotherapeutic adjunct. Compr Psychiatry. 1968;9(5):490\u20138. https:\/\/doi.org\/10.1016\/S0010-440X(68)80080-X.","journal-title":"Compr Psychiatry"},{"issue":"3","key":"2686_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000467984","volume":"8","author":"S Grof","year":"1973","unstructured":"Grof S, Goodman LE, Richards WA, Kurland AA. LSD-Assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatr. 1973;8(3):129\u201344. https:\/\/doi.org\/10.1159\/000467984.","journal-title":"Int Pharmacopsychiatr"},{"issue":"02","key":"2686_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1055\/s-0028-1094301","volume":"4","author":"A Kurland","year":"1971","unstructured":"Kurland A, Savage C, Pahnke WN, Grof S, Olsson JE. LSD in the treatment of alcoholics*. Pharmacopsychiatry. 1971;4(02):83\u201394. https:\/\/doi.org\/10.1055\/s-0028-1094301.","journal-title":"Pharmacopsychiatry"},{"issue":"11","key":"2686_CR24","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/npp.2017.84","volume":"42","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris RL, Goodwin GM. The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacol. 2017;42(11):2105\u201313. https:\/\/doi.org\/10.1038\/npp.2017.84.","journal-title":"Neuropsychopharmacol"},{"key":"2686_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.neuropharm.2018.02.018","volume":"142","author":"SJ Belouin","year":"2018","unstructured":"Belouin SJ, Henningfield JE. Psychedelics: where we are now, why we got here, what we must do. Neuropharmacology. 2018;142:7\u201319. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.02.018.","journal-title":"Neuropharmacology"},{"key":"2686_CR26","unstructured":"U.S. Food and Drug Administration. Psychedelic drugs: Considerations for clinical investigations. Published online June 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/psychedelic-drugs-considerations-clinical-investigations"},{"issue":"4","key":"2686_CR27","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1017\/S1478951522001481","volume":"22","author":"LM Reynolds","year":"2024","unstructured":"Reynolds LM, Barnett B, Weleff J, et al. The perceptions of cancer health-care practitioners in New Zealand and the USA toward psychedelic-assisted therapy with cancer patients: A cross-sectional survey. Pall Supp Care. 2024;22(4):664\u201373. https:\/\/doi.org\/10.1017\/S1478951522001481.","journal-title":"Pall Supp Care"},{"key":"2686_CR28","doi-asserted-by":"publisher","first-page":"204512532412648","DOI":"10.1177\/20451253241264812","volume":"14","author":"B VanderZwaag","year":"2024","unstructured":"VanderZwaag B, Garcia-Romeu A, Garcia-Barrera MA. Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery. Therap Adv Psychopharmacol. 2024;14:20451253241264812. https:\/\/doi.org\/10.1177\/20451253241264812.","journal-title":"Therap Adv Psychopharmacol"},{"issue":"1","key":"2686_CR29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1089\/pmr.2024.0108","volume":"6","author":"M Dorval","year":"2025","unstructured":"Dorval M, Chang SL, Farzin H, et al. Roadmap for equitable access and responsible use of psilocybin-assisted psychotherapy in palliative care. Palliat Med Rep. 2025;6(1):153\u201360. https:\/\/doi.org\/10.1089\/pmr.2024.0108.","journal-title":"Palliat Med Rep"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02686-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-025-02686-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02686-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T13:53:30Z","timestamp":1753106010000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-025-02686-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2686"],"URL":"https:\/\/doi.org\/10.1186\/s13014-025-02686-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6272209\/v1","asserted-by":"object"}]},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. Consent for study participation was obtained from all participants and available upon request. The study was approved by the University of California, Irvine Internal Review Board #3063.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. Consent for study participation was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to Participate"}},{"value":"Consent for publication was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing\u00a0 interests"}}],"article-number":"114"}}